Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effectiveness and Safety of Risperdal CONSTA Added to Usual Treatment in Patients With Bipolar Disorder Who Have Frequent Mood Episodes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must provide informed consent~* Must agree to receive regular injections~* Must have current diagnosis of bipolar disorder I or II~* Must have at least four episodes of mood disorder in the last year that required psychiatric intervention~Exclusion Criteria:~* Female who is or may be pregnant or breastfeeding, who is not at least 1 year postmenopausal, or is not using reliable and adequate birth control~* Psychiatric diagnosis is due directly to effects of a substance or general medical condition~* Substance dependence~* Received treatment with a long-acting injectable antipsychotic less than 2 injection cycles prior to baseline (so, for example, if the drug is injected every 2 weeks, the patient could not enroll in the study if they had received an injection within the last 4 weeks)~* Received Electroconvulsive Therapy (ECT) within the last month~* Began psychotherapy (talk therapy) within 2 months~* In the past month was treated with any of these medications: carbamazepine, oxcarbazepine, fluoxetine, paroxetine, or clozapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): None
- 002 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).